NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 16h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRINALIN is a combination oral extended-release tablet containing azatadine maleate (a first-generation antihistamine) and pseudoephedrine sulfate (a decongestant) approved in 1982. It treats symptoms of allergic rhinitis and upper respiratory allergies by blocking histamine receptors and reducing nasal congestion. The fixed-dose combination provides sustained symptom relief with convenient once or twice-daily dosing.
LOE Approaching
This mature product faces LOE pressure and declining market relevance; small to minimal marketing teams now focus on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRINALIN offers limited career advancement due to its LOE-approaching lifecycle and minimal market traction. Roles focus on defending shelf space, managing declining revenues, and supporting legacy customer accounts rather than growth or innovation.
Brand Manager (defensive)Field Sales Representative
Worked on TRINALIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.